Mike Irvine joins Ablatus as Chief Technology Officer

We are delighted to welcome Mike Irvine to Ablatus as our new Chief Technology Officer.  Mike brings a wealth of experience from the technology world and will be focusing on new product development, project leads and management, as well as business development. Mike has extensive knowledge and understanding of working with Innovate UK awards, needle […]

Tracey Morton joins Ablatus as CFO

We are pleased to announce the appointment of Tracey Morton who is now CFO at Ablatus Therapeutics. Tracey is a Fellow of the Chartered Institute of Management Accountants and has a Masters Degree in Business Law.  She brings a wealth of leadership experience in Life Science and FCMG sectors – her most recent roles include […]

Ablatus secures £500,000 in private finance deal

Our recent work with Innovate UK EDGE innovation and growth specialist Emma Douglas-Beet has helped Ablatus to find the £500,000 match funding it needed to secure an Innovate UK Smart Grant of £1.42 million. Fundraising activity continues alongside ongoing product development. The funds were required for final pre-clinical testing and to create a pre-commercialisation product […]

Ablatus shortlisted for coveted #21toWatch Awards

The 2021 shortlist for the coveted #21toWatch Awards was revealed earlier this week and Ablatus are delighted to have made it onto the shortlist for the prestigious ‘Things’ Award. The list includes some of the most inspirational entrepreneurs, start-ups and innovations from the East of England and being named on the shortlist is a real […]

David Lewis joins Ablatus as CEO

We are delighted to announce the appointment of David Lewis as CEO at Ablatus Therapeutics Ltd.  David has a strong history of delivery within the global medical technology space, having started his career with Johnson & Johnson and CR Bard. David then spent 15 years at Medtronic, holding progressive Senior Leadership roles, which culminated in […]

Ablatus awarded £1M Innovate UK grant

We are delighted to have been awarded over £1M by the UK government to develop our novel minimally invasive treatment for soft tissue tumours.  The award will fund a 2-year project to develop the protype device into a final version for use in patients for the first time. Partnering with Cambridge-based product engineering and design […]

Ablatus Therapeutics receives first CE Mark for Bimodal Electric Tissue Ablation system component

We are delighted to announce that we have received our first CE mark! Our surgical ablation system offers significant advantage over the current standard of care across a variety of therapeutic indications. One of the components of the system is a patient grounding pad which facilitates energy delivery into the targeted tissue. The CE Mark […]

Ablatus Therapeutics achieves ISO 13485:2016 certification

Ablatus has been certified to ISO 13485:2016 following successful audits with BSI. ISO 13485 is a global standard in quality management systems for medical devices that supports polices and processes across the entire business. CEO David Brooks said: “As we continue development of our technology for clinical use, conforming to the ISO 13485 standard is […]

Ablatus reaches final of east of England Investment Catalyst Pitching Day

We are delighted to announce that David Brooks, our CEO, successfully pitched to a panel of investors on 31st October and won a spot at the prestigious final of the East of England Investment Catalyst Pitching Day. David saw off stiff competition from 10 other companies from the Cambridge area and now benefits bespoke support […]

Article in Medical Technology

We are delighted to be in print in issue 18 of Medical Technology. The article is entitled ‘Destroying tumours with next-generation ablation’, here’s brief intro, click here to read the full article. “Radiofrequency ablation (RFA) can destroy solid tumours without the need for invasive surgery. At the forefront is NHS Norfolk and Norwich University Hospital […]